Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Am J Gastroenterol. 2018 Jun 27;113(9):1345. doi: 10.1038/s41395-018-0162-0

Table 3:

Proportion Achieving Treatment Outcomes at 12 Months Stratified by TNF-α Antagonist Exposure Using Non-Response Imputation Analysis

Overall TNFα antagonist
naive		 1 TNFα
antagonist		 ≥ 2 TNFα
antagonists
Response 27%
(n=86/321)		 30%
(n=28/93)		 26%
(n=36/140)		 25%
(n=22/88)
Remission 20%
(n=64/321)		 27%
(n=25/93)		 17%
(n=24/140)		 17%
(n=15/88)
CSF-REM 15%
(n=30/195)		 20%
(n=10/50)		 11%
(n=9/84)		 18%
(n=11/61)
EI 30%
(n=61/203)		 37%
(n=20/54)		 27%
(n=25/92)		 28%
(n=16/57)
ER 17%
(n=35/203)		 22%
(n=12/54)		 16%
(n=15/92)		 14%
(n=8/57)
Deep Remission 14%
(n=28/203)		 22%
(n=12/54)		 12%
(n=11/92)		 9%
(n=5/57)
Colectomy 9%
(n=30/321)		 1%
(n=1/93)		 14%
(n=19/140)		 11%
(n=10/88)

Deep Remission defined as achieving both Clinical Remission and Endoscopic Remission

CSF-REM = corticosteroid-free remission; EI = endoscopic improvement; ER = endoscopic remission